

Special Issue

Breast Cancer: Pathology, Diagnosis and Treatment

Message from the Guest Editor

Breast cancer (BC), the most common female cancer, risk factors include advanced age, obesity, alcohol abuse, smoking, and physical inactivity, higher exposure to estrogen, and postmenopausal hormone replacement therapy. Although most cases of BC are sporadic, a third can be attributed to familial (20–30%) or hereditary (5–10%) causes. In recent decades, basic and translational studies have led to new biological insights, that have contributed to the improvement of diagnostic and treatment options for BC, as well as to the development of predictive and prognostic biomarkers useful to avoid unnecessary treatments. Furthermore, several clinical trials have shown the possible (old and new) toxicities of cancer treatments, suggesting the best management strategies in clinical practice. However, BC management, due to the high heterogeneity of the disease, is still a significant challenge in research. keywords

- breast cancer
- Luminal A/B
- HER2
- triple negative
- CDK4/6 inhibitors
- multigene assays
- antibody-drug conjugate

Guest Editor

Dr. Rita De Sanctis

1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Pieve Emanuele, Milan, Italy
2. Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center—IRCCS, Humanitas Cancer Center, Via Manzoni 56, Rozzano, 20089 Rozzano, Milan, Italy

Deadline for manuscript submissions

closed (16 July 2024)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/147137

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).